- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
- Merck announced on September 3, 2025, that it is seeking potential approval for new drugs from the FDA.
Iovance Biotherapeutics is evaluating its drug Amtagvi with Merck's Keytruda, potentially leading to FDA label expansion.
6 reports, 3 independent
Updated Aug 6
Gone quiet
Reached 3 outlets in its first 24 hours
- Reports
- 6
- Developments
- 1
- Repetition
- 83%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Iovance Biotherapeutics is evaluating its drug Amtagvi with Merck's Keytruda, potentially leading to FDA label expansion.
Who's involved
What this event is mainly aboutKeep exploring
Part of
Merck announced on September 3, 2025, that it is seeking potential approval for new drugs from the FDA.Also in this story
- Merck is seeking FDA approval for its drug Winrevair, based on data from the ZENITH, HYPERION, and Stellar studies.
- The FDA is reviewing TAR-200 for approval, a process involving major pharmaceutical companies like Merck, AstraZeneca, and Pfizer in the oncology space.
- FDA granted Breakthrough Therapy designation for a drug developed by Merck.
Within A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
The entities involved
- FDA
-
Iovance Biotherapeutics
American biopharmaceutical startup
Nothing else this week.
-
Merck
public company in Indonesia
Related events
- Iovance Biotherapeutics received FDA approval for its therapy, and the company is listed on Nasdaq.
- A product was launched in the U.S. market following FDA involvement.
- OS Therapies, Inc. is seeking interim and final review data submissions from regulatory bodies while attending major global investment conferences.
- Merck has set the list price for a drug that received approval from the FDA.
- A study protocol involving a company based in Mont-Saint-Guibert was approved by the U.S. FDA.
Coverage
Newest first; wire copies grouped- ZacksIOVA Stock Drops 6% on $350M Common Stock Offering Iovance Biotherapeutics IOVA recently announced that it is floating a secondary issue of its common stock to raise gross proceeds worth $350 million
- GlobeNewswireIovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) SAN CARLOS, Calif., Aug. 22, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or
- GlobeNewswireIovance Biotherapeutics Reports Financial Results and Corporate Updates for Second Quarter and First Half 2025 $60.0M in 2Q25 Total Product Revenue More than 100 Patients Treated with Amtagvi® in 2Q2
- Motley FoolThis Beaten-Down Healthcare Stock Could Jump 720%, According to a Wall Street Analyst. Is It Time to Buy? Iovance launched its first product, called Amtagvi, last year. Initial sales aren't bad, but